David Oliver, DO
Family Medicine · Ocala, FLNPI 1164404455
Payments from drug & device makers
Across 570 payments — averaging $7962.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$3.3M
- GSK$494K
- Regeneron$224K
- Pfizer$213K
- Novo Nordisk AS$79K
- Tolmar, Inc.$67K
- plus $126K from 18 others
Across 11 payments — averaging $22,091 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$243K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 96 | $3,335,089 |
| GSK | 17 | $494,455 |
| Regeneron | 33 | $223,521 |
| Pfizer | 26 | $213,078 |
| Novo Nordisk AS | 271 | $78,969 |
| Tolmar, Inc. | 17 | $67,143 |
| Bayer | 28 | $47,042 |
| Radius Health, Inc. | 35 | $44,663 |
| Novartis | 1 | $16,892 |
| Janssen Research & Development, LLC | 3 | $12,000 |
| Eli Lilly Export S.A. Puerto Rico Branch | 3 | $3,135 |
| Johnson & Johnson | 8 | $775 |
| Amgen | 11 | $574 |
| Stryker | 3 | $427 |
| Ironwood Pharmaceuticals, Inc | 2 | $193 |
| AbbVie | 2 | $130 |
| Amarin Pharma, Inc. | 2 | $130 |
| Novo Nordisk | 2 | $130 |
| Lilly USA, LLC | 3 | $98 |
| Esperion Therapeutics, Inc. | 1 | $71 |
| Philips North America LLC | 2 | $38 |
| Smith+Nephew | 2 | $35 |
| Organogenesis Inc. | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $13 |
How this compares
$4,538,627 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family medicine in Ocala
- John NardandreaOcala$30.8M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.